tiprankstipranks
Trending News
More News >
Halozyme Therapeutics (HALO)
NASDAQ:HALO
US Market
Advertisement

Halozyme (HALO) Stock Forecast & Price Target

Compare
1,061 Followers
See the Price Targets and Ratings of:

HALO Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
2 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Halozyme
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HALO Stock 12 Month Forecast

Average Price Target

$71.25
▼(-4.91% Downside)
Based on 8 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $71.25 with a high forecast of $91.00 and a low forecast of $51.00. The average price target represents a -4.91% change from the last price of $74.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","69":"$69","92":"$92","57.5":"$57.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$91.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$51.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,57.5,69,80.5,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.02,61.480000000000004,63.940000000000005,66.4,68.86,71.32000000000001,73.78,76.24000000000001,78.7,81.16,83.62,86.08,88.54,{"y":91,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.02,59.96076923076923,60.901538461538465,61.84230769230769,62.783076923076926,63.723846153846154,64.66461538461539,65.60538461538462,66.54615384615384,67.48692307692308,68.42769230769231,69.36846153846155,70.30923076923077,{"y":71.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.02,58.403076923076924,57.78615384615385,57.16923076923077,56.55230769230769,55.93538461538462,55.31846153846154,54.70153846153846,54.08461538461539,53.46769230769231,52.85076923076923,52.23384615384616,51.61692307692308,{"y":51,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.05,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$91.00Average Price Target$71.25Lowest Price Target$51.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HALO
Morgan Stanley
Morgan Stanley
$75$80
Buy
6.77%
Upside
Reiterated
08/17/25
Halozyme's Strong Financial Performance and Growth Potential Justifies Buy Rating
Goldman Sachs Analyst forecast on HALO
Goldman Sachs
Goldman Sachs
$55$56
Hold
-25.26%
Downside
Reiterated
08/12/25
Goldman Sachs Remains a Hold on Halozyme (HALO)
J.P. Morgan Analyst forecast on HALO
J.P. Morgan
J.P. Morgan
$60$63
Hold
-15.92%
Downside
Reiterated
08/07/25
J.P. Morgan Keeps Their Hold Rating on Halozyme (HALO)
Benchmark Co. Analyst forecast on HALO
Benchmark Co.
Benchmark Co.
$75
Buy
0.09%
Upside
Reiterated
08/07/25
Analysts Conflicted on These Healthcare Names: QuidelOrtho (NASDAQ: QDEL), Qiagen (NYSE: QGEN) and Halozyme (NASDAQ: HALO)
Citizens JMP Analyst forecast on HALO
Citizens JMP
Citizens JMP
$78$91
Buy
21.45%
Upside
Reiterated
08/06/25
Citizens JMP Remains a Buy on Halozyme (HALO)
Leerink Partners Analyst forecast on HALO
Leerink Partners
Leerink Partners
$47$51
Sell
-31.94%
Downside
Reiterated
08/06/25
Leerink Partners Remains a Sell on Halozyme (HALO)
TD Cowen
$79
Buy
5.43%
Upside
Reiterated
08/06/25
Positive Outlook and Strong Performance Drive Buy Rating for Halozyme
H.C. Wainwright Analyst forecast on HALO
H.C. Wainwright
H.C. Wainwright
$72$75
Buy
0.09%
Upside
Reiterated
08/06/25
Halozyme's Strong Financial Performance and Growth Prospects Lead to Buy Rating and Increased Price Target
Wells Fargo Analyst forecast on HALO
Wells Fargo
Wells Fargo
$65
Hold
-13.25%
Downside
Reiterated
06/02/25
We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.
Evercore ISI Analyst forecast on HALO
Evercore ISI
Evercore ISI
$55
Buy
-26.60%
Downside
Reiterated
05/15/25
Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).
Piper Sandler Analyst forecast on HALO
Piper Sandler
Piper Sandler
$53
Hold
-29.27%
Downside
Reiterated
03/06/25
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HALO
Morgan Stanley
Morgan Stanley
$75$80
Buy
6.77%
Upside
Reiterated
08/17/25
Halozyme's Strong Financial Performance and Growth Potential Justifies Buy Rating
Goldman Sachs Analyst forecast on HALO
Goldman Sachs
Goldman Sachs
$55$56
Hold
-25.26%
Downside
Reiterated
08/12/25
Goldman Sachs Remains a Hold on Halozyme (HALO)
J.P. Morgan Analyst forecast on HALO
J.P. Morgan
J.P. Morgan
$60$63
Hold
-15.92%
Downside
Reiterated
08/07/25
J.P. Morgan Keeps Their Hold Rating on Halozyme (HALO)
Benchmark Co. Analyst forecast on HALO
Benchmark Co.
Benchmark Co.
$75
Buy
0.09%
Upside
Reiterated
08/07/25
Analysts Conflicted on These Healthcare Names: QuidelOrtho (NASDAQ: QDEL), Qiagen (NYSE: QGEN) and Halozyme (NASDAQ: HALO)
Citizens JMP Analyst forecast on HALO
Citizens JMP
Citizens JMP
$78$91
Buy
21.45%
Upside
Reiterated
08/06/25
Citizens JMP Remains a Buy on Halozyme (HALO)
Leerink Partners Analyst forecast on HALO
Leerink Partners
Leerink Partners
$47$51
Sell
-31.94%
Downside
Reiterated
08/06/25
Leerink Partners Remains a Sell on Halozyme (HALO)
TD Cowen
$79
Buy
5.43%
Upside
Reiterated
08/06/25
Positive Outlook and Strong Performance Drive Buy Rating for Halozyme
H.C. Wainwright Analyst forecast on HALO
H.C. Wainwright
H.C. Wainwright
$72$75
Buy
0.09%
Upside
Reiterated
08/06/25
Halozyme's Strong Financial Performance and Growth Prospects Lead to Buy Rating and Increased Price Target
Wells Fargo Analyst forecast on HALO
Wells Fargo
Wells Fargo
$65
Hold
-13.25%
Downside
Reiterated
06/02/25
We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.
Evercore ISI Analyst forecast on HALO
Evercore ISI
Evercore ISI
$55
Buy
-26.60%
Downside
Reiterated
05/15/25
Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).
Piper Sandler Analyst forecast on HALO
Piper Sandler
Piper Sandler
$53
Hold
-29.27%
Downside
Reiterated
03/06/25
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

1 Month
xxx
Success Rate
17/27 ratings generated profit
63%
Average Return
+4.04%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.96% of your transactions generating a profit, with an average return of +4.04% per trade.
3 Months
xxx
Success Rate
16/27 ratings generated profit
59%
Average Return
+7.11%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +7.11% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
23/23 ratings generated profit
100%
Average Return
+31.53%
reiterated a buy rating last month
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.53% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
100%
Average Return
+51.43%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +51.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HALO Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
3
3
3
0
Buy
16
16
15
14
12
Hold
6
6
6
7
6
Sell
0
1
1
1
1
Strong Sell
0
0
0
0
0
total
22
26
25
25
19
In the current month, HALO has received 12 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. HALO average Analyst price target in the past 3 months is 71.25.
Each month's total comprises the sum of three months' worth of ratings.

HALO Financial Forecast

HALO Earnings Forecast

Next quarter’s earnings estimate for HALO is $1.63 with a range of $1.52 to $1.68. The previous quarter’s EPS was $1.54. HALO beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year HALO has Outperformed its overall industry.
Next quarter’s earnings estimate for HALO is $1.63 with a range of $1.52 to $1.68. The previous quarter’s EPS was $1.54. HALO beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year HALO has Outperformed its overall industry.

HALO Sales Forecast

Next quarter’s sales forecast for HALO is $339.74M with a range of $331.40M to $350.00M. The previous quarter’s sales results were $325.72M. HALO beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year HALO has Outperformed its overall industry.
Next quarter’s sales forecast for HALO is $339.74M with a range of $331.40M to $350.00M. The previous quarter’s sales results were $325.72M. HALO beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year HALO has Outperformed its overall industry.

HALO Stock Forecast FAQ

What is HALO’s average 12-month price target, according to analysts?
Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 71.25.
    What is HALO’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for HALO, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is HALO a Buy, Sell or Hold?
        Halozyme Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.
          What is Halozyme Therapeutics’s price target?
          The average price target for Halozyme Therapeutics is 71.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $91.00 ,the lowest forecast is $51.00. The average price target represents -4.91% Decrease from the current price of $74.93.
            What do analysts say about Halozyme Therapeutics?
            Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
              How can I buy shares of HALO?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis